Clinical trial · Interventional
Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab
Phase 1 Dose Escalation Trial of Intra-Tumoral Injection of Sodium Iodide Simporter (NIS) Measles Virus (Edmonston Strain) in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT02919449CI-TRIAL-00068171terminatedPhase 1Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Low recruitment
Summary
Brief summary (as posted)
This a Phase 1 study designed to determine the maximum tolerated dose (MTD) and toxicity of attenuated Measles virus (MV-NIS) combined with Atezolizumab in patients with recurrent and metastatic NSCLC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Recurrent Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Atezolizumab | Biological | Atezolizumab | ALIAS |
| MV-NIS | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- MV-NIS and Atezolizumab
- description
- MV-NIS will be administered intratumorally as a single dose on day 1. Atezolizumab will be given at day 15 and then every 3 weeks.
- interventionNames
- Biological: MV-NIS
- Biological: Atezolizumab
Primary outcomes (1)
- measure
- Maximum Tolerated Dose (MTD) of MV-NIS in Combination With Atezolizumab
- timeFrame
- 28 days after MV-NIS administration for each dose cohort
- description
- To determine the maximum tolerated dose (MTD) of the intra-tumoral administration of an Edmonston strain MV genetically engineered to produce NIS (MV-NIS), in combination with the PD-L1 inhibitor atezolizumab
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Key Inclusion Criteria: * Diagnosis of metastatic lung cancer, with histologic confirmation of the primary NSCLC histology and with at least one lesion amenable for intra-tumoral injection of MV-NIS. * Patient meets the FDA-approved indication for Atezolizumab treatment in NSCLC. * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1. * Ability to provide informed consent. * Adequate hematological, liver and kidney function. * Must be willing to implement contraception throughout study and for the 8 weeks following last study drug administration. Key Exclusion Criteria: * Any of the following prior therapy: Chemotherapy ≤ 3 weeks prior to registration. Biologic therapy ≤ 4 weeks prior to registration. Radiation therapy ≤ 3 weeks prior to registration * Other concurrent investigational therapy (utilized for a non-FDA-approved indication and in the context of a research investigation). * Pregnant women. * Nursing women. * Men or women of childbearing potential who are unwilling to employ adequate contraception during treatment and 8 weeks following the completion of study drug treatment. * Allergy to measles vaccine or history of severe reaction to prior measles vaccination. * History of organ transplantation.
References
Publications (0)
Data not yet available
No reference posted for this study.